HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response
Pharmacological Research · 2023
DOI: 10.1016/j.phrs.2023.106732 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2023. Verfasst von Mehrdad Hashemi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Depa…. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 369 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High mobility group A 2 (HMGA2) is a protein that modulates the structure of chromatin in the nucleus. Importantly, aberrant expression of HMGA2 occurs during carcinogenesis, and this protein is an upstream mediator of cancer hallmarks including evasion of apoptosis, proliferation, invasion, metastasis, and therapy resistance. HMGA2 targets critical signaling pathways such as Wnt/β-catenin and mTOR in cancer cells. Therefore, suppression of HMGA2 function notably decreases cancer progression and improves outcome in patients. As HMGA2 is mainly oncogenic, targeting expression by non-coding RNAs (ncRNAs) is crucial to take into consideration since it affects HMGA2 function. MicroRNAs (miRNAs) belong to ncRNAs and are master regulators of vital cell processes, which affect all aspects of cancer hallmarks. Long ncRNAs (lncRNAs) and circular RNAs (circRNAs), other members of ncRNAs, are upstream mediators of miRNAs. The current review intends to discuss the importance of the miRNA/HMGA2 axis in modulation of various types of cancer, and mentions lncRNAs and circRNAs, which regulate this axis as upstream mediators. Finally, we discuss the effect of miRNAs and HMGA2 interactions on the response of cancer cells to therapy. Regarding the critical role of HMGA2 in regulation of critical signaling pathways in cancer cells, and considering the confirmed interaction between HMGA2 and one of the master regulators of cancer, miRNAs, targeting miRNA/HMGA2 axis in cancer therapy is promising and this could be the subject of future clinical trial experiments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Genetics, Faculty of Advanced Science and Technology, Tehran…
- Department Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari 4815733971, Iran; The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari…
- Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. Electronic address: houshmandi.kia7@ut.ac.ir.
- Precision Medicine in Oncology (PrMiO), Department of Pathology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands. Electronic address: t.l.m.tenhagen@erasmusmc.nl.
- Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran. Electronic address: Shokoohmoghadam@yahoo.com.
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Orthopedics, Faculty of medicine, Tehran Medical Sciences, I…
Zitieren
APA
Hashemi, M., Rashidi, M., Hushmandi, K., Ten Hagen, T. L. M., Salimimoghadam, S., Taheriazam, A., Entezari, M., & Falahati, M. (2023). HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response. Pharmacological Research. https://doi.org/10.1016/j.phrs.2023.106732
Vancouver
Hashemi M, Rashidi M, Hushmandi K, Ten Hagen TLM, Salimimoghadam S, Taheriazam A, et al. HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response. Pharmacological Research. 2023. doi:10.1016/j.phrs.2023.106732
BibTeX
@article{Hashemi2023,
author = {Hashemi, Mehrdad and Rashidi, Mohsen and Hushmandi, Kiavash and Ten Hagen, Timo L M and Salimimoghadam, Shokooh and Taheriazam, Afshin and Entezari, Maliheh and Falahati, Mojtaba},
title = {HMGA2 regulation by miRNAs in cancer: Affecting cancer hallmarks and therapy response},
journal = {Pharmacological Research},
year = {2023},
doi = {10.1016/j.phrs.2023.106732}
}
EUVIMED